Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bugitinib, Venetoclax, and Cytarabine in Relapsed/Refractory AML
NCT07563179Phase 2Recruiting
- Sponsor
- Shenzhen University General Hospital
- Start
- Apr 2026
- Primary completion
- Jun 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of brigatinib in acute myeloid leukemia (AML), sponsored by Shenzhen University General Hospital. Started Apr 2026; status: recruiting.
02
Drugs
brigatinib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT07563179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07563179.